^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Waldenstrom Macroglobulinemia
    Drug:Imbruvica (ibrutinib) (BTK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    10/21/2014
    Excerpt:
    Imbruvica as a single agent is indicated for the treatment of adult patients with Waldenstrom’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy.
    Evidence Level:
    Sensitive: A1 - Approval
    New
    Source:
    FDA
    Excerpt:
    IMBRUVICA is a kinase inhibitor indicated for the treatment of adult patients with:...Waldenstrom’s macroglobulinemia (WM)…
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Ibrutinib (discussed under other recommended regimens for primary therapy) has been included in the algorithm as a "preferred" single agent for relapsed/refractory WM/LPL.